Framingham firm reports positive pre-clinical results
Framingham-based medical device maker Arch Therapeutics said a third-party, pre-clinical study had obtained favorable data for its surgical product, AC5 Surgical Hemostatic Device.
The study compared AC5’s effectiveness in controlling wound bleeding with the effectiveness of a branded, commercially available fibrin sealant.
The AC5 device, designed to control bleeding and fluid loss during surgical procedures, contains a self-assembling peptide comprised of naturally occurring amino acids that are not sourced from humans or animals. The statement from Arch said that gives AC5 an advantage over commercially available fibrin sealants that use human blood products that are subject to contamination, and that require freezing and multistep preparation.
The study, which used rat livers, is one of an ongoing series of studies comparing AC5 with currently marketed hemostatic products used in surgical procedures, the statement said. The study group intends to submit the data for publication.
WBJ Web Partners
Most Recent
Most Recent
0 Comments